Home Shop Library About Login

Contact

info@liveforeternal.com Mon – Fri, 9am – 5pm Pacific

Recovery

BPC-157

A body protective compound studied extensively for accelerated healing of tendons, ligaments, muscles, and the gut lining.

Read More

Mechanism

BPC-157 is a synthetic 15-amino acid peptide derived from a protective protein found in human gastric juice. It promotes angiogenesis (new blood vessel formation), upregulates growth hormone receptors at injury sites, and modulates nitric oxide pathways to accelerate tissue repair.

Research Areas

  • Tendon and ligament repair
  • Gut and intestinal healing
  • Muscle injury recovery
  • Anti-inflammatory pathways
  • Angiogenesis and wound healing

Research Notes

One of the most extensively studied healing peptides in the literature. Multiple animal studies demonstrate systemic healing properties, with particular strength in musculoskeletal and gastrointestinal research. Commonly studied alongside TB-500 for synergistic recovery protocols.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: 200–500 mcg
  • Cycle length studied: 4–12 weeks
  • Often paired with: TB-500
View in Shop →
TB-500

Synthetic version of Thymosin Beta-4, studied for systemic tissue repair, inflammation reduction, and flexibility.

Read More

Mechanism

TB-500 is a synthetic fragment of the naturally occurring protein Thymosin Beta-4, present in virtually every human and animal cell. It promotes actin regulation, cell migration, and angiogenesis — enabling faster systemic tissue repair and reducing localized inflammation throughout the body.

Research Areas

  • Systemic tissue and muscle repair
  • Inflammation and pain reduction
  • Improved flexibility and range of motion
  • Cardiovascular tissue research
  • Hair follicle growth studies

Research Notes

TB-500's systemic action (vs. BPC-157's more localized effects) makes it a common stack partner. Research suggests complementary mechanisms — BPC-157 targeting specific injury sites while TB-500 supports body-wide repair processes simultaneously.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: 2–5 mg (2000–5000 mcg)
  • Cycle length studied: 4–8 weeks
  • Often paired with: BPC-157
View in Shop →
Wolverine

A pre-mixed recovery blend combining BPC-157 and TB-500 in one vial, pairing localized and systemic tissue repair mechanisms.

Read More

Mechanism

WOLVERINE combines BPC-157 and TB-500 in a single pre-mixed vial. BPC-157 promotes angiogenesis and localized tissue repair at injury sites, while TB-500 supports systemic actin regulation and cell migration — a pairing frequently studied together for complementary, body-wide recovery support.

Research Areas

  • Tendon, ligament, and muscle repair
  • Systemic and localized inflammation reduction
  • Flexibility and range of motion
  • Gut lining and tissue healing

Research Notes

BPC-157 and TB-500 are among the most commonly stacked recovery peptides, with research suggesting their mechanisms complement rather than overlap. WOLVERINE combines both into a single vial for researchers who want this established pairing without preparing two separate compounds.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: combined per component ranges
  • Cycle length studied: 4–8 weeks
  • Format: single-vial pre-mixed blend
View in Shop →

Anti-Aging

GHK-Cu

A naturally occurring copper peptide studied for collagen synthesis, skin regeneration, and cellular renewal.

Read More

Mechanism

GHK-Cu (glycyl-L-histidyl-L-lysine-Cu²⁺) is a naturally occurring copper complex in human plasma that declines with age. It activates over 4,000 human genes involved in tissue remodeling, stimulates collagen and elastin production, and protects cells from oxidative damage.

Research Areas

  • Collagen and elastin synthesis
  • Skin regeneration and wound healing
  • Oxidative stress reduction
  • Hair follicle growth stimulation
  • Anti-inflammatory gene activation

Research Notes

GHK-Cu is among the most researched anti-aging peptides, with documented gene regulatory activity across thousands of pathways. Studies suggest it resets gene expression patterns in aging cells back toward a more youthful state.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: 1–2 mg (1000–2000 mcg)
  • Cycle length studied: 4–12 weeks
  • Often paired with: BPC-157, TB-500
View in Shop →
Glow

A pre-mixed recovery and regeneration blend combining BPC-157, GHK-Cu, and TB-500 in one vial.

Read More

Mechanism

GLOW combines three synergistic compounds in a single pre-mixed vial. BPC-157 drives tissue repair and gut healing, GHK-Cu activates collagen synthesis and skin remodeling, and TB-500 supports systemic anti-inflammation and flexibility — together targeting comprehensive cellular renewal.

Research Areas

  • Skin regeneration and collagen synthesis
  • Tissue and gut lining repair
  • Systemic anti-inflammatory support
  • Cellular renewal and recovery

Research Notes

GLOW pairs GHK-Cu's collagen and regeneration research with the established BPC-157 + TB-500 recovery stack, combining anti-aging and tissue-repair mechanisms into one formulation for researchers studying comprehensive renewal protocols.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: combined per component ranges
  • Cycle length studied: 4–12 weeks
  • Format: single-vial pre-mixed blend
View in Shop →
Klow

An advanced pre-mixed blend building on the GLOW formula with the addition of KPV for enhanced anti-inflammatory support.

Read More

Mechanism

KLOW builds on the GLOW formula (BPC-157, GHK-Cu, TB-500) with the addition of KPV, a tripeptide fragment of alpha-MSH studied for its gut-protective and immune-modulating properties. Together, the four compounds target tissue repair, collagen remodeling, systemic inflammation, and cellular renewal in a single pre-mixed vial.

Research Areas

  • Gut-protective and immune-modulating research
  • Skin regeneration and collagen synthesis
  • Systemic inflammation reduction
  • Tissue repair and cellular renewal

Research Notes

KPV is studied for potent anti-inflammatory and immune-modulating effects, particularly in gut-related research, without the immunosuppressive tradeoffs of some other compounds. Adding it to the GLOW formula extends the blend's focus into gut and immune research alongside its existing regeneration profile.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: combined per component ranges
  • Cycle length studied: 4–12 weeks
  • Format: single-vial pre-mixed blend
View in Shop →

Longevity

MOTS-C

A mitochondria-encoded peptide that regulates metabolic homeostasis, activates AMPK, and supports cellular longevity.

Read More

Mechanism

MOTS-C is a 16-amino acid peptide encoded in mitochondrial DNA. It translocates to the nucleus under metabolic stress and activates AMPK (AMP-activated protein kinase) — a master regulator of energy homeostasis — improving glucose metabolism, fat oxidation, and cellular stress response.

Research Areas

  • Insulin sensitivity and glucose regulation
  • Exercise performance and endurance
  • Longevity and aging pathways
  • Mitochondrial function
  • Obesity and metabolic syndrome research

Research Notes

MOTS-C levels naturally decline with age. Research in animal models demonstrates significant improvements in insulin sensitivity and physical performance. Its unique mitochondrial origin makes it a novel target in aging and metabolic research.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: 5–10 mg
  • Cycle length studied: 4–8 weeks
  • Often paired with: NAD+, SS-31
View in Shop →
NAD+

A coenzyme essential for cellular energy production and DNA repair, studied for its role in aging and metabolic health.

Read More

Mechanism

NAD+ is a coenzyme found in all living cells that plays a central role in energy metabolism and over 500 enzymatic reactions. It activates sirtuins (longevity-associated proteins), supports PARP DNA repair enzymes, and fuels mitochondrial ATP production. Levels decline significantly with age.

Research Areas

  • Cellular energy and ATP production
  • DNA damage repair via PARP activation
  • Sirtuin pathway and longevity signaling
  • Cognitive function and neuroprotection
  • Mitochondrial health and biogenesis

Research Notes

NAD+ research has expanded dramatically in recent years due to its central role in aging biology. Studies in mice demonstrate significant lifespan extension with NAD+ precursor supplementation. Human trials are ongoing, with promising signals in metabolic and cognitive health.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: 500–1000 mg
  • Cycle length studied: ongoing / cyclical
  • Often paired with: MOTS-C, SS-31
View in Shop →
SS-31

A cardiolipin-targeting tetrapeptide studied for mitochondrial protection, ATP restoration, and oxidative stress reduction.

Read More

Mechanism

SS-31 (Elamipretide) is a tetrapeptide that selectively concentrates in the inner mitochondrial membrane, where it binds to cardiolipin — a phospholipid essential for cristae structure and electron transport chain function. This interaction stabilizes mitochondrial architecture, reduces reactive oxygen species (ROS) production, and restores ATP synthesis in damaged cells.

Research Areas

  • Mitochondrial integrity and cardiolipin protection
  • Oxidative stress and ROS reduction
  • ATP production and energy restoration
  • Heart failure and cardiac research
  • Kidney protection and renal aging
  • Skeletal muscle function in aging

Research Notes

SS-31 has been studied in multiple Phase II clinical trials for heart failure with preserved ejection fraction (HFpEF) and acute kidney injury. Preclinical data demonstrates remarkable reversal of mitochondrial dysfunction in aging tissues — making it one of the most clinically advanced mitochondria-targeted compounds in research.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: 0.05–0.25 mg/kg
  • Cycle length studied: acute to 28-day protocols
  • Often paired with: MOTS-C, NAD+
View in Shop →

Growth Hormone

Tesamorelin

A growth hormone-releasing factor analog that stimulates endogenous GH production through the pituitary gland.

Read More

Mechanism

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds to GHRH receptors in the pituitary gland, stimulating the pulsatile release of endogenous growth hormone. Unlike exogenous GH, it preserves the natural feedback loop, resulting in physiological GH secretion and downstream IGF-1 elevation.

Research Areas

  • Visceral adiposity reduction
  • Body composition and muscle preservation
  • IGF-1 support
  • Lipid metabolism
  • Cognitive function in aging

Research Notes

Tesamorelin is FDA-approved (as Egrifta) for HIV-associated lipodystrophy, making it one of the few research peptides with a clinical approval history. Research beyond its approved indication explores its body composition and cognitive benefits, particularly in aging populations.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: 1–2 mg daily
  • Cycle length studied: 26–52 weeks
  • Often paired with: Ipamorelin, CJC-1295
View in Shop →
Ipamorelin

A selective growth hormone secretagogue that stimulates GH release via ghrelin receptor activation, without significantly affecting cortisol or prolactin.

Read More

Mechanism

Ipamorelin is a pentapeptide that selectively activates the ghrelin (growth hormone secretagogue) receptor in the pituitary gland, triggering a pulsatile release of endogenous growth hormone. Its selectivity means it does so without meaningfully raising cortisol, prolactin, or acetylcholine — a specificity profile that distinguishes it from older secretagogues like GHRP-6.

Research Areas

  • Lean mass support
  • Recovery and sleep quality
  • GH pulse amplitude studies
  • Injury and tissue repair
  • Combination protocols with GHRH analogs

Research Notes

Ipamorelin is frequently studied alongside GHRH analogs such as Tesamorelin or CJC-1295, where the two mechanisms are believed to produce a synergistic GH pulse. Its clean selectivity profile has made it one of the most studied secretagogues for minimizing off-target hormonal effects.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: 200–300 mcg per administration
  • Cycle length studied: 12–16 weeks
  • Often paired with: Tesamorelin, CJC-1295
View in Shop →

Cognitive

Semax

A neuroprotective peptide studied for BDNF upregulation, cognitive enhancement, and stress resilience.

Read More

Mechanism

Semax is a synthetic heptapeptide analog of the ACTH(4-7) sequence. It increases brain-derived neurotrophic factor (BDNF) and its receptor TrkB, modulates dopaminergic and serotonergic activity, and exerts neuroprotective effects through anti-oxidative and anti-inflammatory pathways in the CNS.

Research Areas

  • BDNF upregulation and neuroplasticity
  • Focus and cognitive performance
  • Memory consolidation and learning
  • Anxiety and stress resilience
  • Stroke and ischemia neuroprotection

Research Notes

Semax is approved in Russia for stroke treatment and cognitive impairment. Extensive Russian literature documents its neuroprotective and cognitive-enhancing effects. Western research interest is growing, particularly in BDNF-related neuroplasticity studies and nootropic research protocols.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: 200–600 mcg
  • Cycle length studied: 2–4 weeks
  • Often paired with: Selank
View in Shop →
Selank

A synthetic anxiolytic peptide studied for GABA modulation, stress reduction, and cognitive clarity without sedation.

Read More

Mechanism

Selank is a synthetic analog of the immune peptide tuftsin. It modulates GABA-A receptor activity and regulates expression of serotonin, dopamine, and enkephalins in the brain. Unlike classical anxiolytics, it does not cause sedation or dependence, and also upregulates BDNF expression.

Research Areas

  • Anxiety and stress reduction
  • GABAergic modulation without sedation
  • Cognitive clarity and memory
  • Immune system modulation
  • Depression and mood stability research

Research Notes

Selank is approved in Russia as an anxiolytic agent. Research demonstrates anti-anxiety effects comparable to benzodiazepines without addiction potential or sedation. It is frequently studied alongside Semax for a complementary cognitive and mood protocol.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: 200–500 mcg
  • Cycle length studied: 2–4 weeks
  • Often paired with: Semax
View in Shop →

Weight Management

GLP-RT

A tri-agonist targeting GLP-1, GIP, and glucagon receptors, studied for superior metabolic and body composition outcomes.

Read More

Mechanism

GLP-RT acts as a simultaneous agonist at GLP-1, GIP, and glucagon receptors. GLP-1 activation drives satiety and slows gastric emptying; GIP activation enhances insulin secretion and fat metabolism; glucagon receptor activation increases energy expenditure. The combined tri-agonist effect produces additive metabolic benefits beyond what single or dual agonists achieve.

Research Areas

  • Body weight and visceral fat reduction
  • Insulin sensitivity and glucose regulation
  • Lipid profile improvement
  • Energy expenditure and thermogenesis
  • Cardiovascular metabolic risk markers

Research Notes

Clinical research demonstrates weight reductions of up to 24% in obese participants — among the highest documented for any pharmacological agent. Tri-agonism appears to overcome the metabolic compensation seen with single-pathway approaches, suggesting a more complete metabolic reset.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: 1–12 mg weekly (escalating)
  • Cycle length studied: 24–48 weeks
  • Weekly dosing protocol
View in Shop →
GLP-SM

A semaglutide-class compound studied for appetite suppression, glycemic control, and weekly dosing protocols.

Read More

Mechanism

GLP-SM is a long-acting GLP-1 receptor agonist that mimics the incretin hormone glucagon-like peptide-1. Activation of GLP-1 receptors in the hypothalamus suppresses appetite, while peripheral GLP-1 signaling slows gastric emptying and stimulates insulin secretion in a glucose-dependent manner.

Research Areas

  • Appetite suppression and satiety signaling
  • Glycemic control and HbA1c reduction
  • Visceral fat and weight management
  • Cardiovascular risk reduction
  • Non-alcoholic fatty liver disease (NAFLD)

Research Notes

GLP-1 agonists in this class have demonstrated 15–17% body weight reductions in large-scale trials, with additional cardiovascular mortality benefits. The once-weekly dosing schedule is enabled by a fatty acid modification that extends the half-life to approximately 7 days.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: 0.25–2.4 mg weekly
  • Cycle length studied: 68+ weeks
  • Dose escalation over 16–20 weeks
View in Shop →
GLP-TZ

A tirzepatide-class dual agonist targeting both GLP-1 and GIP receptors for superior metabolic outcomes.

Read More

Mechanism

GLP-TZ is a dual incretin receptor agonist that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation complements GLP-1 signaling by enhancing insulin secretion, promoting fat metabolism, and reducing nausea — the latter being a limiting side effect with GLP-1 mono-agonists.

Research Areas

  • Body weight and adiposity reduction
  • Insulin sensitivity and diabetes management
  • Lipid and cholesterol profiles
  • Non-alcoholic steatohepatitis (NASH)
  • Cardiovascular metabolic health

Research Notes

Tirzepatide-class compounds have demonstrated average weight loss of 20–22% in phase 3 trials — surpassing GLP-1 monoagonists. The dual mechanism appears to produce greater fat mass reduction with better tolerability. Research is expanding into heart failure, sleep apnea, and kidney disease.

Reported in Research Literature

The figures below are cited from published research and self-experimentation literature for reference only. They are not usage, dosing, or administration instructions.

  • Dose range studied: 2.5–15 mg weekly
  • Cycle length studied: 72+ weeks
  • Dose escalation over 20 weeks
View in Shop →
For Educational and Research Purposes Only. All information in this library is provided for scientific reference and does not constitute medical advice. Not for human consumption.
Your Cart

Your cart is empty.

Shop Compounds